Search Results - "Waters, Justin S"

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial by Valle, Juan W, Prof, Wasan, Harpreet, MD, Lopes, Andre, MSc, Backen, Alison C, PhD, Palmer, Daniel H, Prof, Morris, Karen, PhD, Duggan, Marian, MSc, Cunningham, David, Prof, Anthoney, D Alan, MD, Corrie, Pippa, MD, Madhusudan, Srinivasan, MD, Maraveyas, Anthony, Prof, Ross, Paul J, MD, Waters, Justin S, PhD, Steward, Will P, Prof, Rees, Charlotte, MD, Beare, Sandy, PhD, Dive, Caroline, Prof, Bridgewater, John A, MD

“…Summary Background Cisplatin and gemcitabine is the standard first-line chemotherapy regimen for patients with advanced biliary tract cancer; expression of…”
Get full text

Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer—Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data by CHAU, Ian, NORMAN, Andy R, CUNNINGHAM, David, WATERS, Justin S, OATES, Jacqui, ROSS, Paul J

“…To identify baseline prognostic factors and assess whether pretreatment quality of life (QoL) predicts survival in patients with locally advanced or metastatic…”
Get full text

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial by Lamarca, Angela, Palmer, Daniel H, Wasan, Harpreet Singh, Ross, Paul J, Ma, Yuk Ting, Arora, Arvind, Falk, Stephen, Gillmore, Roopinder, Wadsley, Jonathan, Patel, Kinnari, Anthoney, Alan, Maraveyas, Anthony, Iveson, Tim, Waters, Justin S, Hobbs, Claire, Barber, Safia, Ryder, W David, Ramage, John, Davies, Linda M, Bridgewater, John A, Valle, Juan W

“…Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine is the standard first-line chemotherapy regimen, but no robust evidence is…”
Get full text

Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply by Lamarca, Angela, Palmer, Daniel H, Wasan, Harpreet Singh, Ross, Paul J, Ma, Yuk Ting, Arora, Arvind, Falk, Stephen, Gillmore, Roopinder, Wadsley, Jonathan, Patel, Kinnari, Anthoney, Alan, Maraveyas, Anthony, Iveson, Tim, Waters, Justin S, Hobbs, Claire, Barber, Safia, Ryder, W David, Ramage, John, Davies, Linda M, Bridgewater, John A, Valle, Juan W

“…Tiffany Foo and colleagues, Giovanni Brandi and colleagues, and Raja Pramanik and colleagues suggested other stratification factors such as progression-free…”
Get full text

Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial by Backen, Alison C., Lopes, Andre, Wasan, Harpreet, Palmer, Daniel H, Duggan, Marian, Cunningham, David, Anthoney, Alan, Corrie, Pippa G., Madhusudan, Srinivasan, Maraveyas, Anthony, Ross, Paul J., Waters, Justin S., Steward, William P., Rees, Charlotte, McNamara, Mairéad G., Beare, Sandy, Bridgewater, John A., Dive, Caroline, Valle, Juan W.

“…Background Advanced biliary tract cancer (ABC) has a poor prognosis. Cediranib, in addition to cisplatin/gemcitabine [CisGem], improved the response rate, but…”
Get full text

Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s Lymphoma by WATERS, J. S, WEBB, A, CUNNINGHAM, D, CLARKE, P. A, RAYNAUD, F, DI STEFANO, F, COTTER, F. E

“…To evaluate the pharmacokinetics and toxicity of an antisense oligonucleotide targeting bcl-2 in patients with non-Hodgkin's lymphoma (NHL) and to determine…”
Get full text

Management of anemia in patients receiving chemotherapy by Waters, Justin S, O'Brien, Mary E R, Ashley, Sue

Get full text

Novel machine learning algorithm to predict response to immunotherapy in patients with small cell and non-small cell lung cancer by Sharma, Lakshya, Choi, Sunyoung, Balaji, Vaishnavi, Joshi, Adwait, Mporas, Iosif, Shi, Jiaqi, Zhao, Yi, Tailor, Vipula, Shah, Riyaz N.H., Waters, Justin S., Adeleke, Sola Michael

“…e13556 Background: Immune checkpoint inhibitors (ICI) are used to manage patients with both small cell (SCLC) and non-small cell (NSCLC) lung cancer. However,…”
Get full text

Immunotherapy toxicity prediction in patients with melanoma using machine learning algorithms by Sharma, Lakshya, Mohan, Esha, Balaji, Vaishnavi, Wong, Jonathan, Joshi, Adwait, Mporas, Iosif, Shi, Jiaqi, Zhao, Yi, Stoll-D'Astice, Amy C., Tailor, Vipula, Powell, Georgie, Alrifai, Doraid, Shah, Riyaz N.H., Waters, Justin S., Adeleke, Sola Michael

“…e21567 Background: Immune checkpoint inhibitor (ICI) related toxicity is common in melanoma patients, but identifying who will experience toxicity can be…”
Get full text

Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial by Hall, Peter S, Swinson, Daniel, Cairns, David A, Waters, Justin S, Petty, Russell, Allmark, Christine, Ruddock, Sharon, Falk, Stephen, Wadsley, Jonathan, Roy, Rajarshi, Tillett, Tania, Nicoll, Jonathan, Cummins, Sebastian, Mano, Joseph, Grumett, Simon, Stokes, Zuzana, Kamposioras, Konstantinos-Velios, Chatterjee, Anirban, Garcia, Angel, Waddell, Tom, Guptal, Kamalnayan, Maisey, Nick, Khan, Mohammed, Dent, Jo, Lord, Simon, Crossley, Ann, Katona, Eszter, Marshall, Helen, Grabsch, Heike I, Velikova, Galina, Ow, Pei Loo, Handforth, Catherine, Howard, Helen, Seymour, Matthew T

“…Older and/or frail patients are underrepresented in landmark cancer trials. Tailored research is needed to address this evidence gap. The GO2 randomized…”
Get more information

Adjuvant chemotherapy by Waters, Justin S, Cunningham, David

Get full text

A restrospective analysis of toxicities encountered with palliative epirubicin, oxaliplatin, and capecitabine (EOX) chemotherapy for advanced esophagogastric cancer by Khakoo, Shelize Sadrudin, Georgiou, Alexandros, Waters, Justin S.

“…Abstract only 162 Background: Palliative chemotherapy for advanced gastric and gastro-oesophageal junctional (GEJ) carcinoma improves tumour related symptoms…”
Get full text

Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial by Hall, Peter S, Swinson, Daniel, Waters, Justin S., Wadsley, Jonathan, Falk, Stephen, Roy, Rajarshi, Tillett, Tania, Nicoll, Jonathan, Cummings, Sebastian, Grumett, Simon Aird, Kamposioras, Konstantinos, Garcia, Angel, Allmark, Christine, Marshall, Helen, Ruddock, Sharon, Katona, Eszter, Velikova, Galina, Petty, Russell D., Grabsch, Heike I., Seymour, Matthew T.

“…Abstract only 4006 Background: Many pts with aGOAC are elderly and/or frail. We previously compared epirubin/ oxaliplatin/ capecitabine (EOCap) vs OCap vs Cap…”
Get full text

ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy by Lamarca, Angela, Palmer, Daniel H., Wasan, Harpreet Singh, Ross, Paul J., Ma, Yuk Ting, Arora, Arvind, Falk, Stephen, Gillmore, Roopinder, Wadsley, Jonathan, Patel, Kinnari, Anthoney, Alan, Maraveyas, Anthony, Waters, Justin S., Hobbs, Claire, Barber, Safia, Ryder, David, Ramage, John, Davies, Linda M, Bridgewater, John A., Valle, Juan W.

“…Abstract only 4003 Background: Level A evidence supports use of CisGem as first-line chemotherapy for ABC; no robust evidence is available for second-line…”
Get full text

Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy by Mirza, Mansoor Raza, Monk, Bradley J., Gil-Martin, Marta, Gilbert, Lucy, Canzler, Ulrich, Follana, Philippe, Waters, Justin S., Kridelka, Frederic, Levy, Tally, Benigno, Benedict B., Woie, Kathrine, Provencher, Diane M., Lueck, Hans-Joachim, Casado Herraez, Antonio, Lesoin, Anne, Buscema, Joseph, Hellman, Kristina, Rimel, Bj, Hazard, Sebastien, Matulonis, Ursula A.

“…Abstract only 5517 Background: Therapeutic paradigms for recurrent OC vary by geography. Maintenance following response to platinum-based chemotherapy (Plat)…”
Get full text

NiCCC (ENGOT-GYN1): A randomized phase II study of nintedanib (BIBF1120) compared to chemotherapy in patients with recurrent clear-cell carcinoma of the ovary or endometrium by Glasspool, Rosalind Margaret, McNeish, Iain A., Paul, James, Lawless, Claire A, Taggart, Diann, Millan, David W. M., McCluggage, W. Glenn, Wilkinson, Nafisa, Barlow, Clare Stephanie, Hall, Geoff, Waters, Justin S., Banerjee, Susana N., Alexandre, Jerome, LE Fur, Nathalie, Westermann, A.M., Coens, Corneel, Jederud, Christina, Mirza, Mansoor Raza

“…Abstract only…”
Get full text

Changes in plasma biomarkers over time in patients (pts) with advanced biliary tract cancer (ABC) treated in the UK ABC-03 randomized phase II trial by Backen, Alison Catherine, McNamara, Mairead G, Lopes, Andre, Wasan, Harpreet, Palmer, Daniel H., Duggan, Marian, Cunningham, David, Anthoney, Alan, Corrie, Philippa, Madhusudan, Srinivasan, Maraveyas, Anthony, Ross, Paul J., Waters, Justin S., Steward, William P., Rees, Charlotte, Beare, Sandy, Bridgewater, John A., Dive, Caroline, Valle, Juan W.

“…Abstract only…”
Get full text

Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma by Waddell, Tom Samuel, Chau, Ian, Peckitt, Clare, Gonzalez, David, Wotherspoon, Andrew, Patel, Bijal, Middleton, Gary William, Wadsley, Jonathan, Ferry, David, Mansoor, Wasat, Crosby, Tom David Lewis, Coxon, Fareeda Y., Smith, David, Waters, Justin S., Iveson, Timothy, Falk, Stephen, Slater, Sarah, Okines, Alicia Frances Clare, Cunningham, David

“…Abstract only…”
Get full text

ABC-03: A randomized phase II trial of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine (CisGem) chemotherapy for patients (pts) with advanced biliary tract cancer (ABC) by Valle, Juan W., Wasan, Harpreet, Jitlal, Mark, Backen, Alison Catherine, Palmer, Daniel H., Duggan, Marian, Cunningham, David, Anthoney, David Alan, Corrie, Philippa, Madhusudan, Srinivasan, Maraveyas, Anthony, Ross, Paul J., Waters, Justin S., Steward, William P., Rees, Charlotte, Beare, Sandy, Dive, Caroline, Bridgewater, John A.

“…Abstract only…”
Get full text

Prognostication in esophagogastric adenocarcinoma (OGA): Factors influencing overall survival (OS) in REAL3 by Waddell, Tom Samuel, Chau, Ian, Peckitt, Clare, Patel, Bijal, Gonzalez de Castro, David, Wotherspoon, Andrew, Middleton, Gary William, Wadsley, Jonathan, Ferry, David, Mansoor, Wasat, Crosby, Tom David Lewis, Coxon, Fareeda Y., Smith, David, Waters, Justin S., Iveson, Timothy, Falk, Stephen, Slater, Sarah, Okines, Alicia Frances Clare, Cunningham, David

“…Abstract only 91 Background: The REAL3 trial evaluated the addition of panitumumab (P) to epirubicin, oxaliplatin and capecitabine (EOC) in advanced OGA. We…”
Get full text